Navigation Links
Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
Date:2/9/2009

REYKJAVIK, Iceland, February 9 /PRNewswire-FirstCall/ -- In a paper published today, scientists at deCODE genetics (Nasdaq: DCGN) and academic colleagues from four continents present a novel insight into the connection between inflammation and heart disease. Through a genome-wide search in some 10,000 Icelanders, the deCODE team discovered several common single-letter variations in the sequence of the human genome (SNPs) that increase levels of eosinophils in the bloodstream. These are a type of white blood cell that fights parasite infection and mediates inflammation. One of these SNPs, located on chromsome 12q24, was then shown to confer increased risk of heart attack through analysis of the genomes of more than 46,000 patients and controls from Iceland, New Zealand, Italy, and the United States. Given the established role of eosinophils in asthma, the deCODE team also analyzed the eosinophil SNPs in more than 50,000 asthmatics and healthy control subjects from the countries above as well as from Germany, Sweden, Australia, and South Korea. A SNP on chromosome 2q12 was associated with increased risk of asthma, and three other SNPs were associated with risk of atopic asthma.

"This is a great example of how our population data and approach enable us to examine complex questions from multiple vantage points. There is broad interest in the connection between inflammation and cardiovascular disease, and our own discoveries on chromosome 9p21 and in the leukotriene pathway have helped to drive this interest. And in today's work, we started by identifying genetic variants involved in a known inflammatory process and then went on to demonstrate that some of those variants were also risk factors for both heart attack and asthma. These discoveries may be used both in drug discovery and to build out our tools for DNA-based risk assess
'/>"/>

SOURCE deCODE genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
4. deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market
5. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
6. deCODE Sells Auction Rate Securities
7. Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)
8. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
9. deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service
10. Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy
11. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- AACC welcomed thousands of medical professionals and ... & Clinical Lab Expo in Atlanta ... revolutionary advancements in clinical testing technology and research ... diagnose patients quickly and accurately and make sure ... As of Wednesday, July 29, more than 17,500 ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Inc. (Nasdaq: OPTR ) announced that additional ... of fidaxomicin in patients with Clostridium difficile ... A. Miller, M.D., at the Digestive Disease Week 2009 ... http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , , The additional data presented ...
... 2 Document sharing inefficiencies in clinical trials cost investigative ... recent online poll by IntraLinks(R), the leading provider of critical ... document-related administrative duties and repetitive requests for information as significant ... of the polling results include: , , ...
... (Nasdaq: NEOG ) announced today that its Scotland-based ... government to research China-specific food safety and plant health issues. ... laboratory in Beijing. Testing methods and data developed in this ... throughout China. , , "This agreement represents a great ...
Cached Biology Technology:Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 2Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 4Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 5Document Management Inefficiencies Cost Clinical Study Sites Time, Money 2Neogen Partners With Chinese Government 2
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... , This release is available in German ... ( Melolontha melolontha ), the European forest cockchafer ( Melolontha ... genus. These insects can damage huge areas of broadleaf trees ... in their guts that help them to digest their woody ...
... (Spain) have mixed waste from the paper industry with ceramic ... brick that has low thermal conductivity meaning it acts as ... "The use of paper industry waste could bring ... considered as waste can be reused as raw material." ...
... University, Finland, have succeeded in organising virus ... materials. These nanomaterials studied by the Finnish ... sensing, optics, electronics and drug delivery. ... nanoparticles have been extensively studied in recent ...
Cached Biology News:Not without my microbes 2Not without my microbes 3Paper waste used to make bricks 2
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
...
... long and outstanding history in the ... ago we became aware that our ... modified to inject Xenopus oocytes. We ... microdispenser to eliminate any tip movement ...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
Biology Products: